Details of the Drug Combination

General Information of Drug Combination (ID: DCVSNIC)

Drug Combination Name
GSK2398852 GSK-2315698
Indication
Disease Entry Status REF
Amyloidosis Phase 1 [1]
Component Drugs GSK2398852   DMZ5A6D GSK-2315698   DMOWTRL
Antibody Antibody

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of GSK2398852
Disease Entry ICD 11 Status REF
Amyloidosis 5D00 Phase 1 [2]
GSK2398852 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serum amyloid P-component (APCS) TTB7VAT SAMP_HUMAN . [3]
------------------------------------------------------------------------------------
Indication(s) of GSK-2315698
Disease Entry ICD 11 Status REF
Amyloidosis 5D00 Phase 1 [3]
GSK-2315698 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serum amyloid P-component (APCS) TTB7VAT SAMP_HUMAN . [4]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8255).
3 ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health.
4 Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15.